Immunotherapeutic targets in non‐small cell lung cancer
Immunology · 2023-02 · 168 (2) · 256-272
DOI: 10.1111/imm.13562 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 25.08.2022. Verfasst von Habib Sadeghirad und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cure Cancer Australia Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5‐year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in‐depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, Louisiana, USA.
- School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
ORCID-Profile: Majid E Warkiani, Arutha Kulasinghe
Förderung
- Cure Cancer Australia Foundation
- National Health and Medical Research Council
Zitieren
APA
Sadeghirad, H., Bahrami, T., Layeghi, S. M., Yousefi, H., Rezaei, M., Hosseini-Fard, S. R., Radfar, P., Warkiani, M. E., O'Byrne, K., & Kulasinghe, A. (2023). Immunotherapeutic targets in non‐small cell lung cancer. Immunology, 168(2), 256-272. https://doi.org/10.1111/imm.13562
Vancouver
Sadeghirad H, Bahrami T, Layeghi SM, Yousefi H, Rezaei M, Hosseini-Fard SR, et al. Immunotherapeutic targets in non‐small cell lung cancer. Immunology. 2023;168(2):256-272. doi:10.1111/imm.13562
BibTeX
@article{Sadeghirad2023,
author = {Sadeghirad, Habib and Bahrami, Tayyeb and Layeghi, Sepideh M and Yousefi, Hassan and Rezaei, Meysam and Hosseini-Fard, Seyed R and Radfar, Payar and Warkiani, Majid E and O'Byrne, Ken and Kulasinghe, Arutha},
title = {Immunotherapeutic targets in non‐small cell lung cancer},
journal = {Immunology},
year = {2023},
volume = {168},
number = {2},
pages = {256--272},
doi = {10.1111/imm.13562}
}
EUVIMED